FEATURED COMPANIES
- NantPharma
- Pfizer
- Rafael Pharmaceuticals
- Tesaro
This “Clear Cell Sarcoma - Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Clear Cell Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Clear Cell Sarcoma: Overview
Clear-cell sarcoma (CCS) is a rare tumor and preferentially arises in soft tissue in the extremities, sometimes referred to as “melanoma of the soft parts” based on evidence of melanocytic differentiation of these cells. Clear cell sarcoma gets its name from the fact that the cells of the tumor look clear under a microscope. Clear cell sarcoma tumors tend to grow attached to tendons in the limbs, especially in the feet and hands. They sometimes develop in the gastrointestinal tract, attached with the bottom layers of the skin, and in locations throughout the torso. Clear cell sarcoma is slightly more common in females than in males and can occur at all age, the mean age at the time of diagnosis is approximately 25 years. CCS is distinguished from malignant melanoma by the presence of a specific fusion of an oncogene EWS/ATF1, which results from a reciprocal translocation.
Symptoms
The symptoms of Clear Cell Sarcoma include:
A diagnosis of Clear Cell Sarcoma is made based upon a thorough clinical evaluation and pathological evaluation. Clear cell sarcoma tumors are often imaged by an MRI and CT scan. Biopsy is done to check, if the tumor is Clear Cell Sarcoma. Genetic testing confirm the diagnosis of Clear Cell Sarcoma.
Treatment
Therapies that are used to treat individuals with Clear Cell Sarcoma includes surgery, radiation therapy, chemotherapy and targeted therapy. Two FDA approved chemotherapies used in the management of soft tissue sarcomas are ifosfamide and doxorubicin. The most promising experimental strategies for treating clear cell sarcoma are targeted therapies, which are designed to target specific features of cancer cells. One type of targeted therapy is a receptor tyrosine kinase inhibitor, which blocks overactive signaling molecules in cancer cells that promote cancer growth.
Clear Cell Sarcoma Emerging Drugs Chapters
This segment of the Clear Cell Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Clear Cell Sarcoma Emerging Drugs
TSR-042: Tesaro
TSR-042 is an investigational anti-programmed death (PD)-1 immunotherapy agent. It is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2. The therapy is currently under Phase II evaluation in Advanced Clear Cell Sarcoma.
CPI-613®: Rafael Pharmaceuticals
CPI-613® (devimistat) is a ketoglutarate dehydrogenase complex and Pyruvate dehydrogenase complex inhibitor. These are the enzymes of TCA cycle, an indispensable process essential to tumor cell multiplication and survival, selectively in cancer cells. CPI-613® is being evaluated in Phase I clinical studies in combination with hydroxychloroquine for patients with Clear Cell Sarcoma of Soft Tissue.
Clear Cell Sarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Clear Cell Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Clear Cell Sarcoma
This report covers around 6+ products under different phases of clinical development like
Clear Cell Sarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Clear Cell Sarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Clear Cell Sarcoma drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
This report will be delivered within 1-3 business days
Geography Covered
- Global coverage
Clear Cell Sarcoma: Overview
Clear-cell sarcoma (CCS) is a rare tumor and preferentially arises in soft tissue in the extremities, sometimes referred to as “melanoma of the soft parts” based on evidence of melanocytic differentiation of these cells. Clear cell sarcoma gets its name from the fact that the cells of the tumor look clear under a microscope. Clear cell sarcoma tumors tend to grow attached to tendons in the limbs, especially in the feet and hands. They sometimes develop in the gastrointestinal tract, attached with the bottom layers of the skin, and in locations throughout the torso. Clear cell sarcoma is slightly more common in females than in males and can occur at all age, the mean age at the time of diagnosis is approximately 25 years. CCS is distinguished from malignant melanoma by the presence of a specific fusion of an oncogene EWS/ATF1, which results from a reciprocal translocation.
Symptoms
The symptoms of Clear Cell Sarcoma include:
- Slow-growing lump
- Fatigue
- Weight loss
- Loss of appetite
- Night sweats
A diagnosis of Clear Cell Sarcoma is made based upon a thorough clinical evaluation and pathological evaluation. Clear cell sarcoma tumors are often imaged by an MRI and CT scan. Biopsy is done to check, if the tumor is Clear Cell Sarcoma. Genetic testing confirm the diagnosis of Clear Cell Sarcoma.
Treatment
Therapies that are used to treat individuals with Clear Cell Sarcoma includes surgery, radiation therapy, chemotherapy and targeted therapy. Two FDA approved chemotherapies used in the management of soft tissue sarcomas are ifosfamide and doxorubicin. The most promising experimental strategies for treating clear cell sarcoma are targeted therapies, which are designed to target specific features of cancer cells. One type of targeted therapy is a receptor tyrosine kinase inhibitor, which blocks overactive signaling molecules in cancer cells that promote cancer growth.
Clear Cell Sarcoma Emerging Drugs Chapters
This segment of the Clear Cell Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Clear Cell Sarcoma Emerging Drugs
TSR-042: Tesaro
TSR-042 is an investigational anti-programmed death (PD)-1 immunotherapy agent. It is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2. The therapy is currently under Phase II evaluation in Advanced Clear Cell Sarcoma.
CPI-613®: Rafael Pharmaceuticals
CPI-613® (devimistat) is a ketoglutarate dehydrogenase complex and Pyruvate dehydrogenase complex inhibitor. These are the enzymes of TCA cycle, an indispensable process essential to tumor cell multiplication and survival, selectively in cancer cells. CPI-613® is being evaluated in Phase I clinical studies in combination with hydroxychloroquine for patients with Clear Cell Sarcoma of Soft Tissue.
Clear Cell Sarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Clear Cell Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Clear Cell Sarcoma
- There are approx. 6+ key companies which are developing the therapies for Clear Cell Sarcoma. The companies which have their Clear Cell Sarcoma drug candidates in the most advanced stage, i. e. phase II include, Tesaro.
This report covers around 6+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Clear Cell Sarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Clear Cell Sarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Clear Cell Sarcoma drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Clear Cell Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Clear Cell Sarcoma.
- In December 2021, Rafael Pharmaceuticals announced that it partners with Sara's Cure and SARC for the launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in combination with Hydroxychloroquine for patients with Clear Cell Sarcoma of Soft Tissue.
- Clear Cell Sarcoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Clear Cell Sarcoma drugs?
- How many Clear Cell Sarcoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Clear Cell Sarcoma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Clear Cell Sarcoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Clear Cell Sarcoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Tesaro
- NantPharma
- Rafael Pharmaceuticals
- Pfizer
- TSR-042
- AMG 337
- CPI-613
- Crizotinib
This report will be delivered within 1-3 business days
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- NantPharma
- Pfizer
- Rafael Pharmaceuticals
- Tesaro
Introduction
Executive Summary
Clear Cell Sarcoma: Overview
In-depth Commercial Assessment
Clear Cell Sarcoma Key Products
Clear Cell Sarcoma- Unmet Needs
Clear Cell Sarcoma- Market Drivers and Barriers
Clear Cell Sarcoma- Future Perspectives and Conclusion
Clear Cell Sarcoma Analyst Views
Clear Cell Sarcoma Key Companies
Appendix
List of Tables
Table 1 Total Products for Clear Cell Sarcoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Clear Cell Sarcoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Executive Summary
Clear Cell Sarcoma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Comparative Analysis
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
In-depth Commercial Assessment
- Clear Cell Sarcoma companies’ collaborations, Licensing, Acquisition - Deal Value Trends
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Comparative Analysis
Clear Cell Sarcoma Key Products
Clear Cell Sarcoma- Unmet Needs
Clear Cell Sarcoma- Market Drivers and Barriers
Clear Cell Sarcoma- Future Perspectives and Conclusion
Clear Cell Sarcoma Analyst Views
Clear Cell Sarcoma Key Companies
Appendix
List of Tables
Table 1 Total Products for Clear Cell Sarcoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Clear Cell Sarcoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
- Tesaro
- NantPharma
- Rafael Pharmaceuticals
- Pfizer
Note: Product cover images may vary from those shown
